jRCT2031240526招募中不适用
A Phase III study to assess the efficacy and safety of STNM01 as a second-line therapy in patients with unresectable pancreatic cancer who failed to respond to first-line chemotherapy
TME Therapeutics Inc.0 个研究点目标入组 250 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 250
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
入选标准
- •Those who have voluntarily signed a written informed consent approved by the Institutional Review Board.
- •Those who are 20 years of age or older at the time of acquisition of consent.
- •Those whose CD8 positive area ratio was confirmed by the histopathological examination performed at screening.
- •Patients with histopathologically confirmed adenocarcinoma and a clinical diagnosis of unresectable advanced pancreatic cancer, including diagnostic imaging. If test results are available prior to the date of informed consent, the results can be used. In addition, if the investigator or subinvestigator (investigator, etc.) diagnosed pancreatic cancer based on a diagnosis made at another medical institution, the results can be used.
- •Patients who received first-line chemotherapy using a gemcitabine hydrochloride-associated regimen for unresectable pancreatic cancer and were judged to have been refractory or intolerant.
- •-Refractory is defined as evidence of radiological or clinical progression.
- •-Intolerant is defined as discontinuation of a gemcitabine hydrochloride-associated regimen for reasons such as delayed recovery from adverse events.
- •Patients diagnosed with cStageIII or cStageIV according to the General Rules for Pancreatic Cancer, 7th Revised and Enlarged Edition (September 2020) at the time of initial diagnosis.
- •Patients with no history of radiotherapy or chemoradiotherapy for the primary disease.
- •Patients with at least 1 measurable primary pancreatic lesion with a maximum diameter of => 10 mm at screening. [Conforms to the measurement methods defined in the New Guideline for Evaluation of Therapeutic Response in Solid Tumors (RECIST) version 1.1 guidelines]
- •Patients who are scheduled to receive nal-IRI/FL as second-line chemotherapy.
- •Patients whose performance status (ECOG PS) is 0 or
- •Patients who can take food orally.
- •Patients whose laboratory test results at screening meet the following criteria:
- •-White blood cell count: => 3,000/mm3
- •-Neutrophil count: => 1,500/mm3
- •-Platelet count: => 100,000/mm3
- •-Hemoglobin: => 10 g/dL
- •-Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): <= 2.5 times the upper limit of normal (<= 5 times the upper limit of normal in patients with liver metastasis)
- •-Creatinine: <= 2.0 mg/dL
- •-Creatinine clearance: => 30 mL/min
- •-Albumin: => 2.5 g/dL
- •-Serum total bilirubin: <= 1.5 times the upper limit of the normal range
- •Patients who are expected to live for at least 2 months from the date of informed consent.
- •Patients who are able to comply with the visits and examinations specified in the protocol.
排除标准
- •Patients with serious complications (intestinal paralysis, intestinal obstruction, difficult-to-control diabetes mellitus, heart disease, blood disease, lung disease, liver failure, renal failure, etc.). Patients with a serious medical history of serious heart disease, hematologic disease, or pulmonary disease.
- •Patients with moderate or severe pleural effusion or ascites.
- •Patients with brain metastasis or a history of brain metastasis.
- •Patients with a history of malignancy other than pancreatic cancer, except for the following:
- •-Malignancies that have been treated with the aim of cure, for which an active disease has not been confirmed within 2 years before the randomization date, and which are considered at low risk of recurrence by the investigator, etc.
- •-Sufficiently treated carcinoma in situ with no signs of disease.
- •Patients with active infections.
- •Patients with residual adverse events of Grade => 2 due to previous surgery, antineoplastic therapy, etc.
- •Note: Grades are based on the Common Terminology Criteria for Adverse Events ver. 5.0, translated into Japanese by the Japan Clinical Oncology Group (JCOG) (Common terminology criteria for adverse events (CTCAE) ver. 5.0-JCOG).
- •Patients with, or having a history of clinically serious allergies.
- •Patients with a bleeding tendency, except for the following:
- •-Patients who are taking anticoagulants or antiplatelet agents can consider suspension of treatment based on the description of gastrointestinal endoscopy with a high risk of bleeding in the Guideline for Gastrointestinal Endoscopy in Patients Taking Antithrombotic Agents and Supplement 2017 of the Guideline for Gastrointestinal Endoscopy in Patients Taking Antithrombotic Agents on Anticoagulants Including Direct Oral Anticoagulants (DOAC).
- •Patients with interstitial lung disease or pulmonary fibrosis.
- •Patients who are positive for hepatitis B virus surface (HBs) antigen, hepatitis C virus (HCV) antibody, or a serologic test for syphilis.
- •Patients with concomitant autoimmune disease requiring immunosuppressive therapy.
- •Patients with psychosis or psychiatric symptoms, for whom participation in the study is considered difficult.
- •Patients for whom the testing specified in the protocol is impossible or restricted.
- •Women who are pregnant, lactating, or possibly pregnant, or who wish to become pregnant during the study.
- •Men who wish to have children or donate sperm during the study period.
- •Fertile men and female participants who do not intend to use contraception under the guidance of the investigator during the treatment period.
- •Those who are currently participating in or plan to participate in other clinical trials during the study period (non-interventional observational studies are allowed). Patients who received another study drug within 28 days before randomization.
- •Patients who have received STNM01 in the past.
- •Patients who are deemed ineligible to participate in the study by the investigators.
结局指标
主要结局
-
Overall survival (OS)
次要结局
- Progression-free survival (PFS)
- Disease control rate (DCR)
- Response rate (RR)
- Quality of life (QOL) assessment
- Percentage of CD3, CD8, and glycosyltransferase 15 (CHST15) positive areas
- Tumor markers
研究者
相似试验
已完成
3 期
A Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in subjects with castrate-resistant prostate cancer.prostate cancer that can't be treated surgically1003859710036958NL-OMON43687Celgene Corporation136
进行中（未招募）
3 期
A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndromeFamilial Chylomicronemia SyndromeGenetic DiseasesISRCTN12904794Arrowhead Pharmaceuticals, Inc.76
尚未招募
不适用
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti-Interleukin [IL]-33 monoclonal antibody [mAb]) in participants with inadequately-controlled chronic rhinosinusitis with nasal polyps (CEREN1 )jRCT2031250095Sanofi K.K.210
进行中（未招募）
不适用
A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and the Results of Stopping and Restarting Brodalumab Treatment in People with Moderate to Severe Plaque Psoriasis: AMAGINE-1EUCTR2012-000651-13-DEAmgen Inc.600
进行中（未招募）
不适用
A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and the Results of Stopping and Restarting Brodalumab Treatment in People with Moderate to Severe Plaque Psoriasis: AMAGINE-1Moderate to severe plaque psoriasisMedDRA version: 18.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-000651-13-PLAmgen Inc.600